Serum thyroid hormone antibodies are frequent in patients with polyglandular autoimmune syndrome type 3, particularly in those who require thyroxine treatment by Vita, Roberto et al.
August 2017 | Volume 8 | Article 2121
Original research
published: 28 August 2017
doi: 10.3389/fendo.2017.00212
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Jacqueline Jonklaas, 
Georgetown University, 
United States
Reviewed by: 
Ilaria Ruffilli, 
University of Pisa, Italy 
Michele Colaci, 
University of Modena and 
Reggio Emilia, Italy 
Onyebuchi Okosieme, 
Cwm Taf University Health Board, 
United Kingdom
*Correspondence:
Roberto Vita  
roberto.vita@yahoo.it
Specialty section: 
This article was submitted to 
Thyroid Endocrinology, 
a section of the journal 
Frontiers in Endocrinology
Received: 05 July 2017
Accepted: 09 August 2017
Published: 28 August 2017
Citation: 
Vita R, Santaguida MG, Virili C, 
Segni M, Galletti M, Mandolfino M, 
Di Bari F, Centanni M and 
Benvenga S (2017) Serum Thyroid 
Hormone Antibodies Are Frequent 
in Patients with Polyglandular 
Autoimmune Syndrome Type 3, 
Particularly in Those Who Require 
Thyroxine Treatment. 
Front. Endocrinol. 8:212. 
doi: 10.3389/fendo.2017.00212
serum Thyroid hormone antibodies 
are Frequent in Patients with 
Polyglandular autoimmune 
syndrome Type 3, Particularly in 
Those Who require Thyroxine 
Treatment
Roberto Vita1*, Maria Giulia Santaguida2, Camilla Virili2, Maria Segni3, Marina Galletti1, 
Mattia Mandolfino1, Flavia Di Bari1, Marco Centanni2,4 and Salvatore Benvenga1,5,6
1 Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, 2 Department of Medico-Surgical 
Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy, 3 Department of Pediatrics and Child Neuropsychiatry, 
Sapienza University of Rome, Rome, Italy, 4 Endocrinology Unit, AUSL Latina, Latina, Italy, 5Master Program on Childhood, 
Adolescent and Women’s Endocrine Health, University of Messina, Messina, Italy, 6 Interdepartmental Program of Molecular & 
Clinical Endocrinology, and Women’s Endocrine Health, University Hospital Policlinico Universitario G. Martino, Messina, Italy
Polyglandular autoimmune syndrome (PAS) type 3 consists of autoimmune thyroid 
disease (AITD) coexisting with ≥1 non-thyroidal autoimmune disease (NTAID) other 
than Addison’s disease and hypoparathyroidism. We evaluated the prevalence and 
repertoire of thyroid hormones antibodies (THAb) in PAS-3 patients. Using a radioim-
munoprecipation technique, we measured THAb (T3IgM, T3IgG, T4IgM, and T4IgG) in 
107 PAS-3 patients and 88 controls (patients with AITD without any NTAID). Based 
on the selective coexistence of AITD with one NTAID (chronic autoimmune gastritis, 
non-segmental vitiligo or celiac disease), patients were divided into group 1 (chronic 
autoimmune gastritis positive, n = 64), group 2 (non-segmental vitiligo positive, n = 24), 
and group 3 (celiac disease positive, n = 15). At least one of the four THAb was detected 
in 45 PAS-3 patients (42.1%) and 28 controls (31.8%, P =  0.14), with similar rates 
in the three PAS-3 groups. The rates of T3Ab, T4Ab, and T3 + T4Ab were similar in 
groups 1 and 2, while in group 3, T3Ab was undetected (P = 0.02). In PAS-3 patients, 
the rate of levothyroxine treatment was greater in THAb-positive patients compared to 
THAb-negative patients (76.7 vs. 56.1%, P = 0.03, RR = 1.4, 95% CI 1.03–1.81). Not 
unexpectedly, levothyroxine daily dose was significantly higher in group 1 and group 3, 
namely in patients with gastrointestinal disorders, compared to group 2 (1.9 ± 0.4 and 
1.8 ± 0.3 vs. 1.5 ± 0.2 μg/kg body weight, P = 0.0005 and P = 0.004). Almost half of 
PAS-3 patients have THAb, whose repertoire is similar if chronic autoimmune gastritis 
or celiac disease is present. A prospective study would confirm whether THAb positivity 
predicts greater likelihood of requiring levothyroxine treatment.
Keywords: thyroid hormone antibodies, chronic autoimmune thyroiditis, chronic atrophic gastritis, non-segmental 
vitiligo, celiac disease
Abbreviations: AITD, autoimmune thyroid disease; L-T4, levothyroxine; NTAID, non-thyroidal autoimmune disease; PAS, 
polyglandular autoimmune syndrome; THAb, thyroid hormones antibodies.
2Vita et al. Thyroid Hormone Antibodies and PAS-3
Frontiers in Endocrinology | www.frontiersin.org August 2017 | Volume 8 | Article 212
inTrODUcTiOn
Polyglandular autoimmune syndromes (PAS) are defined by 
the coexistence of different clusters of autoimmune diseases 
(1). Neufeld and Blizzard (2) originally defined PAS-3 as the 
association between one autoimmune thyroid disease (AITD) 
and one or more non-thyroidal autoimmune diseases (NTAID) 
other than Addison’s disease and hypoparathyroidism, since 
these two last diseases identify PAS-1 and PAS-2, respectively 
(1, 3). NTAID included in PAS-3 were type 1 diabetes mellitus 
(PAS type 3A); autoimmune chronic atrophic gastritis and per-
nicious anemia (type 3B); and vitiligo, alopecia, and myasthe-
nia gravis (type 3C) (2). Subsequently, Betterle defined PAS-3 
based on the different organ-specific and non-organ-specific 
NTAID that are associated with AITD (Hashimoto’s thyroiditis, 
idiopathic myxedema, symptomless autoimmune thyroiditis, 
Graves’ disease, and thyroid-associated ophthalmopathy) 
(4, 5). PAS-3A includes autoimmune endocrine diseases (type 
1 diabetes mellitus, lymphocytic hypophysitis, premature 
ovarian failure, and Hirata’s disease); PAS-3B includes gas-
trointestinal autoimmune diseases (chronic atrophic gastritis, 
pernicious anemia, celiac disease, and chronic inflammatory 
bowel diseases) and hepatic autoimmune diseases (autoim-
mune hepatitis, primary biliary cirrhosis); PAS-3C comprises 
skin autoimmune diseases (vitiligo, alopecia, and urticaria), 
and nervous system autoimmune diseases (myasthenia gravis, 
multiple sclerosis, and stiff-man syndrome); PAS-3D includes 
collagen diseases (lupus erythematosus and its variants, rheu-
matoid arthritis, seronegative arthritis, systemic sclerosis, and 
mixed connective tissue disease), Sjogren syndrome, vasculitis, 
and hematologic autoimmune diseases (Werlhof ’s syndrome 
and antiphospholipid syndrome) (4, 5).
The most common AITD is Hashimoto’s thyroiditis, also 
known as chronic lymphocytic thyroiditis. Like other auto-
immune endocrine diseases, the prevalence of Hashimoto’s 
thyroiditis has shown a remarkable upward trend over the last 
decades (6, 7). The hallmarks of Hashimoto’s thyroiditis are 
the hypoechoic ultrasound pattern of thyroid and the high 
rate of positivity of thyroid autoantibodies (namely, antibod-
ies directed against thyroglobulin and thyroperoxidase) (6). 
Interestingly, a decline in prevalence and serum levels of thyroid 
autoantibodies was noticed over the last decades in patients with 
Hashimoto’s thyroiditis, together with a specular increase in the 
prevalence of thyroid hormones autoantibodies (THAb) (6). 
Indeed, in those patients, the rate of THAb positivity increased 
by eightfold (from 5 to 40%) over the period 1975–2005 
(6, 8). THAb are found in patients with Graves’ disease in around 
one-third of cases (8, 9). Also, the real prevalence of THAb 
may be underestimated because they are not routinely assayed 
and can appear transiently in serum (8, 10). THAb, which can 
be found in approximately 1% of the general population, are 
directed against T3, T4, or both, and may belong to IgM, IgG, 
or both classes (8, 11). Our group has shown that at least one 
THAb can be found in sera of patients with NTIAD even more 
frequently compared to AITD, regardless of thyroglobulin and/
or thyroperoxidase antibodies status. For instance, in primary 
Sjogren syndrome or rheumatoid arthritis, the rate of THAb 
positivity was 55 or 40%, respectively, and has increased steadily 
over the last years (8, 9). Recently, the highest rates of THAb 
positivity were found in patients with type 1 diabetes mellitus 
or vitiligo, since approximately all of them carried at least one 
THAb (12–14).
Because never studied before, we evaluated the prevalence and 
repertoire of THAb in PAS-3 patients.
sUBJecTs anD MeThODs
This study complies with the Declaration of Helsinki. Informed 
consent has been obtained from each patient after full explana-
tion of the purpose and nature of all procedures used. Since this 
was not an interventional study, we did not need any approval by 
the Internal Review Board.
Our cohort consists of 107 consecutive PAS-3 patients (90 
females, 17 males, F:M ratio = 5.3:1), aged 15–82 years at first 
observation and associated blood sampling. All patients had 
one AITD [Hashimoto’s thyroiditis (n = 103), Graves’ disease 
(n = 4)] associated with at least one NTAID. On the basis of 
the three most prevalent NTAID (chronic atrophic gastritis, 
non-segmental vitiligo, and celiac disease), we divided the 
107 patients into three mutually exclusive groups. In group 1 
patients (n = 66; 61.7%), HT coexisted with chronic atrophic 
(autoimmune) gastritis alone (n = 42) or chronic atrophic gas-
tritis plus at least another NTAID (n = 24) (Table 1). In group 
2 patients (n = 26; 24.3%), HT coexisted with non-segmental 
vitiligo alone (n = 24) or non-segmental vitiligo plus at least 
another NTAID (n = 2) (Table 1). Finally, in group 3 patients 
(n =  15; 14.0%), HT coexisted with only celiac disease and 
no patient presented with celiac disease plus another NTAID 
(Table 1).
The control group was previously studied to also serve as a 
control group in another setting (9). It consisted of a previously 
cohort of 88 Hashimoto’s thyroiditis patients (77 women, 11 men, 
F:M ratio = 7:1; age 42 ± 9 years) who had never been treated with 
levothyroxine (L-T4) and, importantly, had no NTAID.
Diagnosis of autoimmune Diseases
Hashimoto’s thyroiditis was defined by hypoecheoic and inho-
mogeneous echopattern with or without positivity of either 
or both thyroid autoantibodies (thyroglobulin antibodies 
and thyroperoxidase antibodies) (6, 15). Diagnosis of chronic 
atrophic gastritis was based on parietal cell antibodies positiv-
ity and histological confirmation (i.e., focal or complete loss 
of oxyntic glands and/or replacement by metaplastic pyloric 
or intestinal glands) (16). According to the Vitiligo European 
Task Force definition (17), non-segmental vitiligo was defined 
by the presence of white patches of skin, generally symmetrical 
and growing in size. Celiac disease was supported by positiv-
ity of serum transglutaminase antibodies (IgG and IgA) and/
or endomysial antibodies (IgG and IgA). Celiac disease was 
histologically confirmed after duodenum and jejunum biop-
sies showing various degrees of intestinal atrophy and crypt 
hyperplasia according to the Marsh classification, as modi-
fied by Oberhuber (18).
TaBle 1 | Demographics of patients and controls according to AITD and NTAID.
group
aiTD
selective naiTD
1 (n = 66)
hT or gDa
cag
2 (n = 26)
hT
nsV
3 (n = 15)
hT or gDa
cD
all (n = 107)
hT + gD
cag + nsV + cD
Other naiTD
Only one (selective) 42 24 15 76
Two 19 2 0 23
Three 5 0 0 8
Four or more 0 0 0 0
Most frequent naiTD
Pernicious anemia 13 0 0 13
Rheumatoid arthtritis 3 0 0 0
Sjogren syndrome 3 0 0 0
Other indices
Age, years 55.4 ± 13.6 45.5 ± 14.1 37.4 ± 12.2 50.5 ± 15.0
Gender (females, males) (F:M ratio) 61, 5 (12.2:1) 16, 10 (1.6:1) 13, 2 (6.5:1) 90, 17 (5.3:1)
Under L-T4 replacement n = 45 (68.2%) n = 16 (61.5%) n = 6 (40%) n = 67 (62.6%)
Not to overload the table we have shown only the most frequent NTAID, namely, those in ≥3 patients.
AITD, autoimmune thyroid disease; CAG, chronic autoimmune gastritis; CD, celiac disease; GD, Graves’ disease; HT, Hashimoto’s thyroiditis; NAITD, non-autoimmune thyroid 
disease; NSV, non-segmental vitiligo.
aOnly four patients had GD as AITD, two of them were in group 1 and another two in group 3.
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Thyroid hormone autoantibodies (Thab) 
assay
We assayed serum THAb (T3IgM, T3IgG, T4IgM, and T4IgG) 
by a previously described radioimmunoprecipitation technique 
(10, 12, 19). Five hundred microliters of serum, which had been 
stored at –20°C, were incubated with 0.5 μCi [125I]T3 or [125I]
T4 (Johnson and Johnson, Milan, Italy) for 60  min at 23°C. 
Twenty microliters of this mixture were incubated with 150 µL 
solution containing antihuman IgM or antihuman IgG serum 
(Sigma-Aldrich, Milan, Italy) at a concentration of 0.5% for 24 h 
at 4°C. Both antihuman IgM and antihuman IgG serum had been 
prediluted 1:10 with saline containing BSA. The mixture obtained 
was then centrifuged at 2,000 × g for 20 min, and the supernatant 
was aspirated. T3Ab and T4Ab were assayed in two different runs. 
We also assayed THAb in negative and positive controls, namely 
sera negative for all four types of THAb or sera positive for one 
type of THAb (T3IgM, T3IgG, T4IgM, or T4 IgG). Each serum 
was analyzed in duplicate for each THAb. THAb positivity was 
defined by a proportion of the [125I]T3 or [125I]T4 immunoprecipi-
tated by the corresponding antiserum >3.9%, >3.6%, >3.4%, or 
>3.9% for T3IgM, T3IgG, T4IgM, or T4IgG, respectively (10, 12, 
19). In case of borderline values, assay was repeated.
statistics
Data are reported as mean ± SD. Comparisons between propor-
tions were handled with the χ2-test or the Fisher’s exact test as 
appropriate. Comparisons between continuous variables were 
handled with the Mann–Whitney test or the Kruskal–Wallis test 
as appropriate. Level of significance was set at 0.05.
resUlTs
Demographics
The mean age at first observation in the 107 PAS-3 patients was 
50.5 years (range 15–82 years). Group 1 patients were significantly 
older compared with group 2 (55.4 ± 13.6 vs. 45.5 ± 14.1 years, 
P  =  0.004) and group 3 (55.3  ±  13.8 vs. 37.4  ±  12.2  years, 
P  <  0.0001) patients, while group 3 patients were younger, 
although not significantly, compared to group 2 patients (P = 0.06) 
(Table 1). Not unexpectedly patients with chronic autoimmune 
gastritis were the oldest, as this autoimmune disease peaks some 
decades later (16) in contrast with non-segmental vitiligo (17) 
and celiac disease (20).
The female-to-male ratio (F:M) was significantly greater 
in group 1 than in group 2 (61:5 or 12.2:1 vs. 16:10 or 1.6:1, 
P = 0.0008).
Excluding the four patients with Graves’ disease, at first obser-
vation, 67/107 HT patients (62.6%) were under replacement L-T4 
therapy, with similar intragroup rates (group 1, 45/66, 68.2%; 
group 2, 16/26, 61.5%; group 3, 6/15, 40%).
Prevalence and repertoire of Thab
All data are summarized in Table 2. Overall, THAb were detected 
in 45/107 patients (42.1%), without significant differences 
between groups (43.9, 42.3, and 33.3% in groups 1, 2 and 3, 
respectively).
Single THAb were the most prevalent (36.4%), again with no 
intergroup differences (33.3–37.9%), whereas quadruple THAb 
were always absent. Within the single THAb category, the four 
types of THAb were distributed similarly in groups 1 and 2 
(df = 3, χ2 = 2.2, P = 0.53), but dissimilarly between groups 1 
and 3 (df =  3, χ2 =  14.4, P =  0.002) or between groups 2 and 
3 (df =  3, χ2 =  10.7, P =  0.01). Because of very low or absent 
types of THAb in the double, triple, or quadruple categories, no 
intergroup statistics was possible (Table 2).
Concerning categorization based on the thyroid hormones 
bound (i.e., T3 only, T4 only, and T3 plus T4), groups 1 and 2 did 
not differ. In contrast, because of the selective binding of T4 by 
THAb in group 3 patients, this group differed from both group 
1 (df = 2, χ2 = 10.8, P = 0.005) and group 2 (df = 2, χ2 = 7.3, 
TaBle 2 | Prevalence and repertoire of THAb.
Thab
aiTD + cag
n = 66
group 1
aiTD + nsV
n = 26
group 2
aiTD + cD
n = 15
group 3
Pas-3
n = 107
all
hTa
n = 88
controls
T3ab T4ab
igM igg igM igg
No No No No 37 (56.1%) 15 (57.7%) 10 (66.7%) 62 (57.9%) 60 (68.2%)
At least one of the four +ve 29 (43.9%) 11 (42.3%) 5 (33.3%) 45 (42.1%) 28 (31.8%)
single Thab 25 (37.9%) 9 (34.6%) 5 (33.3%) 39 (36.4%) 19 (21.6%)
+ No No No 13 (19.7%) 3 (11.6%) 0 16 (14.9%) 2 (2.3%)
No + No No 5 (7.6%) 3 (11.6%) 0 8 (7.5%) 6 (6.8%)
No No + No 2 (3.0%) 0 4 (26.7%) 6 (5.6%) 8 (9.1%)
No No No + 5 (7.6%) 3 (11.5%) 1 (6.7%) 9 (8.4%) 3 (3.4%)
Double Thab 3 (4.5%) 2 (7.7%) 0 5 (4.7%) 9 (10.2%)
+ + No No 2 (3.0%) 1 (3.8%) 0 3 (2.8%) 5 (5.7%)
+ No + No 0 0 0 0 1 (1.1%)
No No + + 0 0 0 0 1 (1.1%)
No + + No 0 0 0 0 1 (1.1%)
No + No + 0 0 0 0 0
+ No No + 1 (1.5%) 1 (3.8%) 0 2 (1.9%) 1 (1.1%)
Triple Thab 1 (1.5%) 0 0 1 (0.9%) 0
+ + + No 1 (1.5%) 0 0 1 (0.9%) 0
+ No + + 0 0 0 0 0
No + + + 0 0 0 0 0
+ + No + 0 0 0 0 0
Quadruple Thab
+ + + + 0 0 0 0 0
Based on hormone bound
T3 only (IgM, IgG, or both) 20 (30.3%) 7 (26.9%) 0 27 (25.2%) 13 (14.8%)
T4 only (IgM, IgG, or both) 7 (10.6%) 3 (11.5%) 5 (33.3%) 15 (14.0%) 12 (13.6%)
T3 and T4 (IgM, IgG, or both) 2 (3.0%) 1 (3.8%) 0 3 (2.8%) 3 (3.4%)
All absent 37 (56.1%) 15 (57.7%) 10 (66.7%) 62 (57.9%)  60 (68.2%)
Based on ig class
IgM only (T3, T4, or T3 + T4) 15 (22.7%) 3 (11.5%) 4 (26.7%) 22 (20.6%) 11 (12.5%)
IgG only (T3, T4, or T3 + T4) 10 (15.1%) 6 (23.1%) 1 (6.7%) 17 (15.9%) 9 (10.2%)
IgM and IgG (T3, T4, or T3 + T4) 4 (6.1%) 2 (7.7%) 0 6 (5.6%) 8 (9.1%)
All absent 37 (56.1%) 15 (57.7%) 10 (66.7%) 62 (57.9%) 60 (68.2%)
For abbreviations, see Table 1 footnote.
aAt time of blood sampling, there was no non-thyroid autoimmune disease associated with HT.
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P =  0.03). In regard to categorization based on the immuno-
globulin classes of THAb (i.e., IgM only, IgG only, and IgM plus 
IgG), group 3 did not differ from the other two groups (χ2 = 1.6, 
P = 0.45 vs. group 1; χ2 = 4.0, P = 0.13 vs. group 2), with groups 1 
and 2 not differing either (χ2 = 2.0, P = 0.37) (Table 2).
Six of the 13 group 1 patients with pernicious anemia carried 
one THAb (three patients carried T4IgG, two patients T3IgM, and 
one patient T4IgM). Only one patient of the three with rheumatoid 
arthritis or Sjogren syndrome was THAb positive (T3IgM).
Prevalence and repertoire of Thab in 
Pas-3 Patients compared to controls
Table 2 also compares the repertoire of THAb in PAS-3 patients 
with that of the HT only patients. Even though the rate of THAb 
positivity (i.e., positivity for at least one THAb) was similar (42.1 
vs. 31.8%, P = 0.14), the four types of THAb were dissimilarly 
distributed in PAS-3 patients and controls (df =  3, χ2 =  8.6, 
P = 0.03), the greatest difference being between group 1 patients 
and controls (df = 3, χ2 = 11.7, P = 0.009). Concerning categoriza-
tion based on the thyroid hormones bound, in PAS-3 patients, the 
most prevalent THAb were against T3 (25.2%) compared to those 
against T4 (14%) or both T3 and T4 (2.8%). In contrast, the cor-
responding rates in controls were 14.8, 13.6, and 3.4% (P = 0.51) 
(Table 2). PAS-3 patients and controls did not differ either in the 
repertoire of THAb based on immunoglobulin classes (P = 0.27) 
(Table 2).
association of Thab with number  
of nTaiD
The average number of NTAID was the highest in group 1 
patients, the lowest in group 3 patients, and intermediate in 
group 2 patients (1.4 vs. 1.0 vs. 1.1, P = 0.0009). Indeed, around 
one-third (36.4%) of group 1 patients had at least two NTAID, in 
contrast with 2/26 (7.7%) patients in group 2 and none in group 
3 (36.4 vs. 7.7% vs. 0, df = 2, χ2 = 13.9, P = 0.0009).
association of Thab with replacement 
l-T4 Therapy in Pas-3 Patients
Seventy patients (65.4%) were on L-T4 replacement therapy 
at the time of blood sampling. THAb-positive PAS-3 patients 
5Vita et al. Thyroid Hormone Antibodies and PAS-3
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were more likely to be on L-T4 compared to THAb-negative 
patients (76.7 vs. 56.1%, P = 0.03, RR = 1.4, 95% CI 1.03–1.81). 
Furthermore, there was no difference in the frequency of replace-
ment therapy considering either thyroid hormones bound or 
classes of immunoglobulin (data not shown). In the remaining 
37 patients who did not take L-T4, serum TSH levels were similar 
in THAb-positive and THAb-negative patients (3.4  ±  1.8 vs. 
3.4 ± 3.0 mU/L, P = 0.51).
The mean L-T4 daily dose was 1.8 ± 0.4 μg/kg body weight 
and was greater in group 1 and group 3 patients (1.9 ± 0.4 and 
1.8  ±  0.3  μg/kg body weight) compared to group 2 patients 
(1.5 ± 0.2 μg/kg body weight, P = 0.0005 and P = 0.004, respec-
tively). L-T4 daily dose did not change significantly according 
to THAb status (THAb positive 1.7 ± 0.3 μg/kg body weight vs. 
THAb negative 1.9 ± 0.5 μg/kg body weight, P = 0.12).
DiscUssiOn
In this study, we have shown that in PAS-3 patients, THAb are 
found frequently, namely in 4 out of 10. By comparing data 
of PAS-3 patients with only Hashimoto’s thyroiditis (whose 
THAb positivity rate is three out of 10), we infer, as mentioned 
earlier, that the presence of NTAID in the background of 
Hashimoto’s thyroiditis adds little influence on the propen-
sity to form THAb, with negligible influence of associated 
NTAID on thyroid hormones bound by THAb and classes of 
immunogloblulin.
Detection of one or more THAb in PAS-3 patients cannot be 
explained only by the presence of a mere genetic background, 
namely proclivity of these patients to produce antibodies against 
autoantigens. THAb are autoantibodies directed against epitopes 
of thyroglobulin containing iodinated tyrosines, which can form 
T3 only, T4 only, or both T3 and T4 (11). As demonstrated previ-
ously (10) in Hashimotos’ thyroiditis patients who were THAb 
negative prior to undergo diagnostic fine-needle aspiration 
biopsy (FNAC), the appearance in serum of THAb is preceded by 
the FNAC-elicited release of iodinated and heterologous moie-
ties of thyroglobulin that were absent prior to FNAC. Leakage 
of such thyroglobulin molecules may occur naturally in the time 
course of Hashimotos’ thyroiditis, for instance during phases of 
aggravation of the autoimmune inflammation (8). Inflammatory 
cytokines may disclose hidden thyroglobulin epitopes, which are 
capable to elicit autoantibodies production by B-lymphocytes 
that infiltrate the thyroid (8). Post-translational modifications 
of thyroglobulin may increase its antigenicity by better exposing 
the said hormonogenic epitopes (21). For instance, in patients 
with type 1 diabetes mellitus, glycosylated thyroglobulin might 
elicit THAb synthesis with high frequency (12). One possible 
explanation for the detection of THAb in NTAID per se is that a 
very initial autoimmune inflammation of the thyroid is already 
present in NTAID. Indeed, the early stages of lymphocytic 
thyroiditis are characterized by serum reactivity against either 
thyroid hormone, even though thyroglobulin antibodies that 
can be assayed by conventional methods are undetectable (22). 
Another explanation is that material leaking from the inflamed 
peripheral tissues of NTAID patients (e.g., joints, stomach, 
intestinum, and skin) and, regardless of sharing molecular mim-
icry with thyroglobulin, binds thyroid hormones, thus forming 
novel iodinated autoantigens (8).
Concerning the THAb repertoire, double or triple THAb 
positivity was much less common compared to single positivity. 
Particularly, of the 52 THAb detected in the 45 THAb-positive 
PAS-3 patients, three-fourth (39/52, 75%) were directed against 
either T3 or T4. Concerning hormone specificity of THAb, while 
in groups 1 and 2, T3Ab outnumbered T4Ab, and in group 3, 
the distribution was inverted. This difference resembled that 
found in patients with type 1 diabetes mellitus, in which the rate 
of T3Ab or T4Ab positivity was 38.5% (20/52) or 27.1% (12/52) 
(12). Interestingly, no patient of this cohort had type 1 diabetes 
mellitus. In patients with only Hashimoto’s thyroiditis, T3Ab and 
T4Ab were equally distributed (Table 2). Classes of THAb varied 
remarkably among groups, with a preponderance of T3IgM or 
T4IgM in group 1 or group 3, and similar rates of T3IgM, T3IgG, 
and T4IgG in group 2. Thus, overall, primary immune response 
(i.e., IgM) prevailed over a stable secondary immune response 
(i.e., IgG).
Concerning additional NTAID, they were more common in 
group 1. This was not unexpected, since those patients were older 
than group 2 and group 3 patients (see above). The most common 
additional NTAID was pernicious anemia, which was found in 
1/4 patients with chronic atrophic gastritis. Pernicious anemia 
results from vitamin B12 deficiency and may occur in patients 
with advanced chronic inflammation of the gastric corpus. In up 
to 80% of patients with pernicious anemia, autoantibodies against 
intrinsic factor, which impair vitamin B12 absorption, are found 
(16, 23).
THAb positivity was associated with a greater risk of hypothy-
roidism (RR = 1.4, 95% CI 1.03–1.81) regardless of the hormone 
bound or the class of immunoglobulin. Indeed, more than 3/4 
THAb-positive PAS-3 patients had required L-T4 as thyroid 
replacement, in contrast with around half of THAb-negative 
PAS-3 patients. Not unexpectedly patients with the greatest 
requirements of L-T4 were those with gastric autoimmune 
gastritis or celiac disease, two disorders that are associated with 
impaired intestinal absorption of L-T4 (24–27). For instance, 
patients with chronic atrophic gastritis need a 27% increase 
in L-T4 dose in order to achieve target serum TSH levels (24, 
28). Furthermore, atrophic gastritis can be associated with a 
long-standing Helicobacter pylori infection in up to 30% of cases 
(16, 29). Compared to H. pylori-negative patients, those with a 
concurrent H. pylori infection need a greater increase in L-T4 
dose (+34 vs. +24%) (24).
One limitation of this otherwise novel study is its cross-sec-
tional design. Therefore, we could not evaluate (i) the occurrence 
of other NTAID over time based on THAb status, (ii) the switch 
of immune response from IgM to IgG, and (iii) changes of the rate 
of hypothyroidism over time based on THAb status.
In conclusion, almost half of PAS-3 patients have THAb, whose 
repertoire is similar in the group with autoimmune gastritis and 
the group with celiac disease. A prospective study would confirm 
whether THAb positivity predicts a greater likelihood of requir-
ing L-T4 treatment over the years.
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This study complies with the Declaration of Helsinki. 
Informed consent has been obtained from each patient after 
full explanation of the purpose and nature of all procedures 
used.
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